Overview Dividends

(ALGN) Align Technology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0162551016

Clear Aligners, Intraoral Scanners, CAD/CAM Software, Whitening System

Health Care Supplies
Market Cap in USD: 11,310m
IPO / Inception: 2001-01-26
Return 12m vs S&P 500: -32.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of ALGN over the last years for every Quarter: "2020-12": 2.61, "2021-03": 2.49, "2021-06": 3.04, "2021-09": 2.87, "2021-12": 2.83, "2022-03": 2.13, "2022-06": 2, "2022-09": 1.36, "2022-12": 1.73, "2023-03": 1.82, "2023-06": 2.22, "2023-09": 2.14, "2023-12": 2.42, "2024-03": 2.14, "2024-06": 2.41, "2024-09": 2.35, "2024-12": 2.44, "2025-03": 2.13, "2025-06": 2.49, "2025-09": 2.61, "2025-12": 0,
EPS CAGR: -47.18%
EPS Trend: -16.6%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of ALGN over the last years for every Quarter: 2020-12: 834.52, 2021-03: 894.771, 2021-06: 1010.808, 2021-09: 1015.906, 2021-12: 1031.099, 2022-03: 973.219, 2022-06: 969.553, 2022-09: 890.348, 2022-12: 901.515, 2023-03: 943.147, 2023-06: 1002.173, 2023-09: 960.214, 2023-12: 956.726, 2024-03: 997.431, 2024-06: 1028.49, 2024-09: 977.872, 2024-12: 995.219, 2025-03: 979.262, 2025-06: 1012.449, 2025-09: 995.692, 2025-12: null,
Rev. CAGR: -0.93%
Rev. Trend: 35.4%
Last SUE: 0.56
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 42.0%
Value at Risk 5%th 62.0%
Relative Tail Risk -10.31%
Reward TTM
Sharpe Ratio -0.19
Alpha -43.61
CAGR/Max DD -0.15
Character TTM
Hurst Exponent 0.411
Beta 1.246
Beta Downside 0.702
Drawdowns 3y
Max DD 67.59%
Mean DD 36.04%
Median DD 38.93%

Description: ALGN Align Technology January 02, 2026

Align Technology (NASDAQ: ALGN) operates two core segments: the Clear Aligner segment, which markets the Invisalign family of clear aligners, Vivera retainers, and related orthodontic accessories for patients ranging from children to adults; and the Imaging Systems & CAD/CAM Services segment, which sells iTero intra-oral scanners, exocad design software, and a suite of digital workflow tools for restorative and orthodontic practices.

In its most recent fiscal year (2023), Align reported revenue of roughly $5.1 billion, a year-over-year increase of about 20 %, and an adjusted operating margin near 22 %. The company shipped roughly 12 million Invisalign aligners and over 1.2 million iTero scanners, reflecting continued market penetration and strong repeat-purchase rates among dental professionals.

Key growth drivers include the expanding global demand for cosmetic orthodontics (the market is projected to grow at a CAGR of ~7 % through 2028), accelerating adoption of digital dentistry platforms that improve treatment efficiency, and macro-level trends such as higher discretionary spending in developed economies and an aging population seeking aesthetic dental solutions.

For a deeper, data-driven look at ALGN’s valuation and scenario analysis, the ValueRay platform provides a concise, research-ready overview.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (378.4m TTM) > 0 and > 6% of Revenue (6% = 239.0m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 3.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 14.25% (prev 13.48%; Δ 0.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 656.1m > Net Income 378.4m (YES >=105%, WARN >=100%)
Net Debt (-883.3m) to EBITDA (745.3m) ratio: -1.19 <= 3.0 (WARN <= 3.5)
Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (72.4m) change vs 12m ago -3.13% (target <= -2.0% for YES)
Gross Margin 68.41% (prev 69.98%; Δ -1.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 63.22% (prev 62.21%; Δ 1.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 365.5 (EBITDA TTM 745.3m / Interest Expense TTM 1.56m) >= 6 (WARN >= 3)

Altman Z'' 3.62

(A) 0.09 = (Total Current Assets 2.53b - Total Current Liabilities 1.97b) / Total Assets 6.23b
(B) 0.39 = Retained Earnings (Balance) 2.42b / Total Assets 6.23b
(C) 0.09 = EBIT TTM 571.7m / Avg Total Assets 6.30b
(D) 1.09 = Book Value of Equity 2.48b / Total Liabilities 2.28b
Total Rating: 3.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.94

1. Piotroski 7.0pt
2. FCF Yield 5.43%
3. FCF Margin 14.23%
4. Debt/Equity 0.03
5. Debt/Ebitda -1.19
6. ROIC - WACC (= -1.58)%
7. RoE 9.75%
8. Rev. Trend 35.36%
9. EPS Trend -16.57%

What is the price of ALGN shares?

As of January 10, 2026, the stock is trading at USD 172.79 with a total of 743,948 shares traded.
Over the past week, the price has changed by +10.74%, over one month by +8.67%, over three months by +31.03% and over the past year by -18.54%.

Is ALGN a buy, sell or hold?

Align Technology has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALGN.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the ALGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 179.8 4.1%
Analysts Target Price 179.8 4.1%
ValueRay Target Price 173.5 0.4%

ALGN Fundamental Data Overview January 04, 2026

P/E Trailing = 30.2971
P/E Forward = 14.556
P/S = 2.8398
P/B = 2.8311
P/EG = 0.9335
Beta = 1.859
Revenue TTM = 3.98b USD
EBIT TTM = 571.7m USD
EBITDA TTM = 745.3m USD
Long Term Debt = 121.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 121.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -883.3m USD (from netDebt column, last quarter)
Enterprise Value = 10.43b USD (11.31b + Debt 121.3m - CCE 1.00b)
Interest Coverage Ratio = 365.5 (Ebit TTM 571.7m / Interest Expense TTM 1.56m)
FCF Yield = 5.43% (FCF TTM 566.6m / Enterprise Value 10.43b)
FCF Margin = 14.23% (FCF TTM 566.6m / Revenue TTM 3.98b)
Net Margin = 9.50% (Net Income TTM 378.4m / Revenue TTM 3.98b)
Gross Margin = 68.41% ((Revenue TTM 3.98b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 64.20% (prev 69.94%)
Tobins Q-Ratio = 1.67 (Enterprise Value 10.43b / Total Assets 6.23b)
Interest Expense / Debt = 1.29% (Interest Expense 1.56m / Debt 121.3m)
Taxrate = 40.09% (38.0m / 94.7m)
NOPAT = 342.5m (EBIT 571.7m * (1 - 40.09%))
Current Ratio = 1.29 (Total Current Assets 2.53b / Total Current Liabilities 1.97b)
Debt / Equity = 0.03 (Debt 121.3m / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = -1.19 (Net Debt -883.3m / EBITDA 745.3m)
Debt / FCF = -1.56 (Net Debt -883.3m / FCF TTM 566.6m)
Total Stockholder Equity = 3.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.01% (Net Income 378.4m / Total Assets 6.23b)
RoE = 9.75% (Net Income TTM 378.4m / Total Stockholder Equity 3.88b)
RoCE = 14.29% (EBIT 571.7m / Capital Employed (Equity 3.88b + L.T.Debt 121.3m))
RoIC = 8.83% (NOPAT 342.5m / Invested Capital 3.88b)
WACC = 10.41% (E(11.31b)/V(11.43b) * Re(10.51%) + D(121.3m)/V(11.43b) * Rd(1.29%) * (1-Tc(0.40)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.26%
[DCF Debug] Terminal Value 72.11% ; FCFF base≈489.2m ; Y1≈558.3m ; Y5≈769.9m
Fair Price DCF = 136.7 (EV 8.92b - Net Debt -883.3m = Equity 9.80b / Shares 71.7m; r=10.41% [WACC]; 5y FCF grow 16.51% → 2.90% )
EPS Correlation: -16.57 | EPS CAGR: -47.18% | SUE: -4.0 | # QB: 0
Revenue Correlation: 35.36 | Revenue CAGR: -0.93% | SUE: 0.56 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.42 | Chg30d=+0.012 | Revisions Net=+3 | Analysts=10
EPS next Year (2026-12-31): EPS=10.95 | Chg30d=+0.004 | Revisions Net=+4 | Growth EPS=+7.5% | Growth Revenue=+3.6%

Additional Sources for ALGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle